WHO Drug Information Vol. 14, No. 2, 2000
(2000; 73 pages) Voir le document au format PDF
Table des matières
Afficher le documentPreface
Ouvrir ce répertoire et afficher son contenuGeneral Policy Issues
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentPneumococcal vaccine: recommendations for use
Afficher le documentValaciclovir: neuropsychiatric reactions
Afficher le documentZanamivir: revisions to labelling
Afficher le documentCelecoxib: adverse reaction reports
Afficher le documentOlanzapine: serious reactions
Afficher le documentInfliximab approved for rheumatoid arthritis
Afficher le documentTenecteplase: the first "clot buster"
Afficher le documentBupropion: a new approach to smoking cessation
Afficher le documentDoxorubicin for ovarian cancer
Afficher le documentLinezolid: the first oxazolide antimicrobial approved
Afficher le documentGuidance for adverse reactions labelling
Afficher le documentLegislation adopted in Europe on orphan drugs
Afficher le documentMore drug safety measures planned in Japan
Afficher le document"Street drug alternatives" are not dietary supplements
Afficher le documentTamsulosin: syncope now reported
Afficher le documentDapsone hypersensitivity syndrome
Afficher le documentKava extract linked to hepatitis
Afficher le documentGene therapy and patient protection
Ouvrir ce répertoire et afficher son contenuEssential Drugs - WHO Model Prescribing Information
Ouvrir ce répertoire et afficher son contenuRecent Publications and Sources of Information
Afficher le documentProposed International Nonproprietary Names: List 83
Afficher le documentSelected WHO Publications of Related Interest
 

Dapsone hypersensitivity syndrome

Singapore - A 22-year-old serviceman on an oversees training exercise in Brunei, received 100 mg dapsone and 12.5 mg pyrimethamine (Maloprim®) weekly as antimalarial chemoprophylaxis.

Two weeks later, he developed fever which was resolved by taking paracetamol but was followed by sudden onset of pruritus on both hands. Pruritic papular rash appeared on hands and feet and progressed to the trunk. Fever returned with chills, left cervical and right inguinal lymphadenopathy and hepatosplenomegaly. Maloprim® was discontinued. On admission to hospital he was afebrile and had bilateral periorbital swelling. The arms, legs and trunk were covered by an erythematous papular rash and petechiae on the feet. The skin had begun to exfoliate. After four days' treatment with oral prednisolone and hydroxyzine he recovered.

Reference: Singapore Adverse Drug Reaction News, Volume 2 (1), March 2000.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013